irbshare: streamlining irb review of multisite studies
TRANSCRIPT
IRBshare: Streamlining IRB Review of Multisite Studies
IRBshare Background>30 Institutions
CTSA Leadership, IRB Directors,
Lawyers, Clinical Trial Experts
SponsorsEli Lily, NIH, VA
Regulatory Expertise OHRP, AAHRPP, WIRB
Funded by National Center for Research Resources (NCRR) (2011-2014)
*New* model envisioned because use of IRB reliance was rare due to Significant lack of trust between IRBsInstitutional/IRB policies against transferring oversight (still true for some institutions)
Initial Project GoalsMaintain high level of protection for human subjects in multicenter trialsAccelerate study start UpCreate a scalable IRB reliance model (minimal funding required; open to all institutions)Create transparency between IRBs to promote shared expertise and practices
Shared Review Model
1. Local investigator submits study to local IRB
2. Study reviewed according to risk level (expedited or full committee review)
upload
IRBshare SystemIRB Approved Documents
1. Local investigator submits study to local IRB (abbrev application recommended)
2. Study reviewed by local subcommittee (>1 IRB member) using IRBshare documents
LEAD IRB LOCAL OVERSIGHT IRB
Committee Responsibility: 1. Determine whether study meets all
federal regulatory guidelines for approval of research (e.g., 45 CFR 46.111)
Subcommittee Responsibility:1. Verify (not re-review) Lead IRB’s
determination, AND 2. Review for site’s own local context
issues
IRB applicationConsent form(s) (become model consent(s))
Protocol + IB/Device ManualMeeting minutes (redacted)
Determination letter
download
LOCAL IRB MAINTAINS OVERSIGHT
BUSINESS AS USUAL
Initial Study ReviewContinuing ReviewStudy-wide amendments
IRBshare is NOT a Central IRB
Reduce duplicative IRB reviews and thus study start upNational reliance model supported by single master agreement for use with
any study regardless of disease type, funder or type of human subjects review required
Ancillary reviews remain under local purview (biosafety, radiation safety, research billing/Medicare qualifying review)
Opportunity to streamline submission processes for investigators
COMMONALITIES WITH OTHER RELIANCE MODELS
IRBshare is NOT a Central IRB
Minimal burden on Lead IRB Minimal process changes for local IRBsNo additional funds required for IRBsNo investigator confusion regarding submissions or reporting: investigators
always go to local IRBNever requires multiple submissions by a site investigator (e.g., to cIRB and
local IRB) Avoids complex IRB negotiations around compliance, COI management, and
reporting)Provides transparency to promote consistent determinations, sharing of best
practices, and communication between IRBs
DIFFERENCES FROM OTHER RELIANCE MODELS
Preliminary Results and Lessons LearnedIRBSHARE MASTER AGREEMENT FINALIZED: OCTOBER 2012
FIRST RELIANCE: FEBRUARY 2013
IRBshare Scope and EligibilityInstitutions
Any institution with an FWA and federally constituted IRBAAHRPP accreditation is not required, but captured for relying sites’ decision making
StudiesAll diseases and conditionsAll studies that require IRB review All funders: Federal, industry, and investigator-initiated
IRB Reviews IncludedAll Phases of Review: Initial study review, continuing review, and reviews of amendments
IRBshare Successes National Reliance Model:
◦ 59 institutions in 28 states have executed single master reliance agreement◦ No funding required to support use
Accelerating Study Start Up: Median of 14 days from submission to approval (n=28 reliances; 79% studies are greater than minimal risk)
Transparency◦ Shared Expertise—Institutions unable to transfer oversight can streamline their review◦ Shared Practices—IRBs communicating and sharing documents/templates
IRBshare Network (n=59)
*AAHRPP accredited (n=44); †CTSA institution (n=39)
States (n=28):AlabamaArizona
ArkansasCalifornia
FloridaIllinoisIowa
KansasKentuckyLouisiana
MaineMassachusetts
MichiganMississippiMinnesota
New MexicoNew York
North CarolinaOhio
OregonPennsylvania
South CarolinaTennessee
TexasUtah
VirginiaWest VirginiaWashington
(Washington DC)
Baystate Health* Oregon Health & Science University† University of Illinois Chicago*†
Boston University Medical Center*† Pennington Biomedical Research Center* University of Iowa*†
Children’s National Medical Center*† St. Claire Regional Medical Center University of Kansas*†
Cincinnati Children’s Hospital Medical Center*† Seattle Children’s Hospital University of Kentucky*†
Columbia University*† Stanford University*† University of Miami†
Duke University*† Texas A&M University University of New Mexico Health Sciences Center*†
Louisiana State University A & M* The Rockefeller University*† University of North Carolina at Chapel Hill *†
Louisiana State University HSC New Orleans* The Scripps Research Institute† University of Pennsylvania*†
Louisiana State University HSC Shreveport* The University of Arizona* University of Pittsburgh*†
Maine Medical Center* The University of Texas HSC at Houston*† University of Southern California*†
Marshall University* The University of Utah*† University of Texas HSC at San Antonio*†
Medical University of South Carolina*† Tufts Medical Center† University of Texas Southwestern Medical Center†
Mayo Clinic*† Tufts University † University of Washington†
Meharry Medical College† Tulane University* Vanderbilt University*†
Michigan State University* University of Alabama Birmingham*† Virginia Commonwealth University*†
Mississippi State University* University of Arkansas for Medical Sciences*† Wake Forest University Health Sciences*
Mount Sinai Medical School*† University of California, Los Angeles†* Washington University (St. Louis) *†
New York University School of Medicine*† University of California, San Diego† West Virginia University*
North Shore LIH Health System University of California, San Francisco*† Xavier University (Louisiana)
Northwestern University † University of Cincinnati*†
Challenges (to all reliance models)
Identifying studies
IRB and PI understanding of responsibilities
Coordination of use/Implementation across diverse studies and institutions
Competing IRB priorities
Managing expectations of IRBs and PIs (IRB reliance ≠ relinquishing HRPP or PI responsibilities)
Using IRBshare
Coordinating Use of IRBshare
1. Identifying a Lead IRB◦ Naturally occurring (1st with IRB approval) ◦ Select IRB based on experience, IRB willingness, site visit schedule
2. While Lead IRB seeking approval◦ Recruit non-IRBshare sites◦ Site investigators notify IRB of study + IRBshare; inquire about submission procedures
3. Once Lead IRB has approval, disseminate approved documents to other study sites◦ Approved consent becomes model consent
4. Site investigators submit (initial, continuing and amendment reviews) and report (adverse events) to the local IRB following local submission policies
◦ Local IRB uses streamlined review to approve◦ Follow study protocol/direction from sponsor when reporting serious adverse events
Industry-sponsor Registration
IRBs not on project whitelist cannot access study documents
IRBshare Admin adds sites to project per sponsor instruction